Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, ...

Investigator-led SwissNET registry analysis showed longer real-world progression-free and overall survival for patients re-treated with 177 Lu-edotreotide compared to those receiving ...

Boston, Sept. 27, 2026 (GLOBE NEWSWIRE) -- Siemens Healthineers introduces Accela, the first radiotherapy system that allows for single breath-hold stereotactic treatments and enables multi-site SBRT ...

The QUASAR Penta‑Guide Performance Phantom combines a broad range of imaging and machine QA checks with integrated analysis software. By reducing the need for multiple phantoms, repeated setups and ...

WASHINGTON, Sept. 27, 2026 (GLOBE NEWSWIRE) -- TamaBio Company Limited, a Japanese medical technology company developing synthetic biomembranes and regenerative medical devices, will exhibit at the ...

Chrysalis Health, one of the nation’s largest providers of comprehensive mental health services, and Curaechoice, one of the leading architects for redefining how self-funded employers connect ...

With over 100 Canadian-made supplements, Herba earns its second consecutive appearance and ranks No. 9 in the Health Care & Wellness category.

Lanier Recovery Center, a Joint Commission-accredited addiction treatment provider serving the greater Atlanta area, now offers a virtual intensive outpatient program (virtual IOP) for adults in ...

The three-day congress features keynote speaker Robert Herjavec and a live Venture Forum where healthcare founders pitch to investors and strategic partners.

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib ...

In preclinical models of pancreatic cancer, Annamycin’s antitumor activity appears to depend in part on CD8+ T cells, the immune system’s primary tumor-killing cells. The finding suggests Annamycin ...

For further information: Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc. Tel: (780) 448-1400, E-mail: madi@questpharmatech.com Neither TSX Venture Exchange nor its Regulation Services Provider (as ...